ArticleJournal of nanobiotechnology2025
Activated microglial exosomes enhance α-Synuclein internalization and accelerate neurodegeneration in lewy body dementia.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oral milk-derived exosomes loaded with tafatinib for anti-inflammatory therapy.International journal of pharmaceutics: X · 2026Article
- The Roles of Macrophage Lineage Cells (MLCs) in Brain Aging.CNS neuroscience & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Lewy body dementia (LBD), which includes Parkinson's disease dementia and dementia with Lewy bodies, is characterized by progressive cognitive decline, α-synuclein (α-Syn) aggregation, and concurrent microglial activation and neuroinflammation. The nucleus basalis of Meynert (NBM), the primary source of cortical cholinergic input, plays a key role in cognitive function and is particularly affected in LBD. Cholinergic neurons within the NBM are highly vulnerable to Lewy body pathology, yet the underlying mechanisms remain poorly understood. In this study, we employed a mouse model with PFF injections into the NBM to investigate how microglia and their exosomes influence α-Syn pathology. We found that exosomes derived from activated microglia exacerbate α-Syn deposition and cognitive deficits, whereas microglial depletion mitigates these pathological changes. In vitro, activated microglial exosomes enhanced the uptake of exogenous α-Syn by cholinergic neurons. Mechanistically, we discovered that microglial exosomes can transfer bioactive membrane receptors to neurons. Focusing on lymphocyte-activation gene 3 (LAG3), a receptor critical for α-Syn internalization, we demonstrated that LAG3 is abundant in exosomes from activated-but not resting-microglia. These exosomes deliver LAG3 to neuronal membranes via an endosomal recycling pathway, a process facilitated by elevated cholesterol content, thereby promoting α-Syn uptake. Together, these findings indicate that microglial exosomes function not only as carriers of signaling molecules but also as vectors for receptor transfer, reshaping neuronal membrane composition. Our results provide a mechanistic explanation for the heightened vulnerability of NBM cholinergic neurons in LBD and reveal a novel pathway in which LAG3-rich microglial exosomes drive neuronal α-Syn internalization, advancing our understanding of neurodegeneration and identifying potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.